育龄期高CD4女性启用依非韦伦方案的肝毒性与肝相关死亡
基于PROMISE试验中3576例CD4≥350细胞/μL的HIV感染孕妇,分析启用含依非韦伦方案后的肝毒性。启用后2.5%发生严重肝毒性,发生率2.3/100人年,肝相关死亡发生率0.07/100人年,年龄较大与严重肝毒性相关。
要点
- 启用依非韦伦后严重肝毒性发生率为2.3/100人年,需监测肝功能。
- 严重肝毒性者中3.3%死于依非韦伦相关肝毒性,提示致命风险。
- 年龄每增加5岁,严重肝毒性风险 adjusted HR 1.35。
核心结论
- 育龄期高CD4女性启用依非韦伦后严重肝毒性发生率为2.5%,严重肝毒性者中3.3%发生肝相关死亡。
研究设计与样本
- PROMISE试验中3576例ART初治、CD4≥350细胞/μL且ALT≤2.5倍正常上限的HIV感染孕妇,随机接受不同ART策略并随访。
主要发现
- 2435例(68%)在产后中位121.1周启用依非韦伦,启用后2.5%(61/2435)发生3级及以上肝毒性,发生率2.3(95%CI 2.0-2.6)/100人年。
- 严重肝毒性事件发生于产后1至132周,其中8.2%(5/61)有症状,3.3%(2/61)死于依非韦伦相关肝毒性。
关键数值与推荐
- 肝毒性按Division of AIDS毒性表定义,严重肝毒性为3级或以上。
- 入组条件为CD4计数≥350细胞/μL且ALT≤2.5倍正常上限。
临床怎么用
- 对育龄期高CD4女性启用含依非韦伦方案时应关注年龄因素并监测肝毒性及肝相关死亡风险。
局限性
- 原文摘要未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Severe hepatotoxicity in people with human immunodeficiency virus (HIV) receiving efavirenz (EFV) has been reported. We assessed the incidence and risk factors of hepatotoxicity in women of childbearing age initiating EFV-containing regimens. METHODS: In the Promoting Maternal and Infant Survival Everywhere (PROMISE) trial, ART-naive pregnant women with HIV and CD4 count ≥ 350 cells/μL and alanine aminotransferase ≤ 2.5 the upper limit of normal were randomized during the antepartum and postpartum periods to antiretroviral therapy (ART) strategies to assess HIV vertical transmission, safety, and maternal disease progression. Hepatotoxicity was defined per the Division of AIDS Toxicity Tables. Cox proportional hazards models were constructed with covariates including participant characteristics, ART regimens, and timing of EFV initiation. RESULTS: Among 3576 women, 2435 (68%) initiated EFV at a median 121.1 weeks post delivery. After EFV initiation, 2.5% (61/2435) had severe (grade 3 or higher) hepatotoxicity with an incidence of 2.3 (95% confidence interval [CI], 2.0-2.6) per 100 person-years. Events occurred between 1 and 132 weeks postpartum. Of those with severe hepatotoxicity, 8.2% (5/61) were symptomatic, and 3.3% (2/61) of those with severe hepatotoxicity died from EFV-related hepatotoxicity, 1 of whom was symptomatic. The incidence of liver-related mortality was 0.07 (95% CI, .06-.08) per 100 person-years. In multivariable analysis, older age was associated with severe hepatotoxicity (adjusted hazard ratio per 5 years, 1.35 [95% CI, 1.06-1.70]). CONCLUSIONS: Severe hepatotoxicity after EFV initiation occurred in 2.5% of women and liver-related mortality occurred in 3% of those with severe hepatotoxicity. The occurrence of fatal events underscores the need for safer treatments for women of childbearing age.
引用
- Bhattacharya D, Gupta A, Tierney C, et al. Hepatotoxicity and Liver-Related Mortality in Women of Childbearing Potential Living With Human Immunodeficiency Virus and High CD4 Cell Counts Initiating Efavirenz-Containing Regimens. Clin Infect Dis. 2021. PMID: 32161944. doi:10.1093/cid/ciaa244
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。